BioCentury | Nov 11, 2020
Emerging Company Profile

CatalYm: opening up tumors to immune cells

...Growth differentiation factor 15GFRAL – GDNF family receptor alpha likeICAM-1 (CD54) – Intercellular adhesion molecule-1LFA-1 (CD11a-CD18)PD-1...
BioCentury | Sep 1, 2020
Politics, Policy & Law

Proposed CMS pathway could be expanded to give therapies, diagnostics immediate, national coverage

A medical devices reimbursement rule proposed by CMS could lay the groundwork for innovative medicines to be covered by Medicare immediately after FDA approval. The proposed rule, which applies only to...
BioCentury | Aug 28, 2020

BARDA enlisting start-ups in fight against COVID-19 via JLABS collaboration

...a small molecule activator of VLA-4 and CD11a-CD18...
...detection and recovery surveillance. TARGETSCas13d – CRISPR-associated protein 13dCD11a-CD18...
BioCentury | Aug 28, 2020
Distillery Therapeutics

Preventing thrombosis using nanoparticles loaded with anti-G protein peptides

DISEASE CATEGORY: Cardiovascular INDICATION: Ischemia/reperfusion injury Nanoparticles loaded with a peptide inhibitor of GNA13, a G protein subunit, could treat cardiac ischemia/reperfusion injury. The...
BioCentury | Feb 4, 2020
Product Development

Insmed planning Phase III for rare lung disorder therapy following mixed Phase II readout

Insmed rose $8.34 (41%) to $28.88 on Monday, gaining $745 million in market cap, after its chronic lung inflammation therapy met the primary endpoint in a Phase II study. But the data, which included an...
BioCentury | Jan 24, 2020
Preclinical News

Jan. 23 Preclinical Quick Takes: Metastasis-associated cancer-associated fibroblast populations; plus NIH-TeneoBio and Basilea

Cancer-associated fibroblast subsets linked to metastasis In a study published in Nature Communications , a team from Institut Curie and INSERM identified within breast cancer patients’ lymph nodes four subpopulations of cancer-associated fibroblasts (CAFs). Two subsets...
BioCentury | Oct 3, 2019
Targets & Mechanisms

ALS platform trial to put neuroinflammation hypothesis to the test

The largest test of the idea that ALS is driven by neuroinflammation will come from the first collaborative platform trial in the disease, which could blow open the range of pathways and targets in play...
BioCentury | May 22, 2019
Financial News

May 22 Financial Quick Takes: $250M for Insmed; plus downgrade for Woodford and more

Insmed raises $250M follow-on Insmed Inc. (NASDAQ:INSM) raised $250 million in a follow-on through the sale of 9.6 million shares at $26. The price is a 7% discount to Insmed's Monday close of $28.07, when...
BioCentury | Feb 22, 2019
Emerging Company Profile

Gyroscope complements dry AMD

Gyroscope Therapeutics Ltd.’s complement-targeting gene therapy for dry age-related macular degeneration could have an edge over competing therapies that are dosed chronically or target complement downstream of its key immune mediators. On Feb. 19, Gyroscope...
BioCentury | Jan 8, 2019
Distillery Therapeutics


INDICATION: Pain Mouse studies suggest inhibiting inflammatory macrophages could help treat Type II diabetes-associated pain. In a mouse model of Type II diabetes, the macrophage-targeting immunotoxin Mac1-saporin decreased disease-induced mechanical allodynia compared with vehicle. Also...
Items per page:
1 - 10 of 207